Full Year 2023 Investor Presentation
39
Investor presentation
Full year 2023
B-cell function
Diabetes is a chronic disease requiring treatment
intensification over time
Diet and exercise
OAD
GLP-1
Insulin
Distribution of estimated prescriptions¹ and value
across treatment classes
3%
9%
49%
22%
3%
13%
40%
14%
0.7%
5%
23%
18%
Time
Estimated Prescriptions
■GLP-1 Inj.
DPP-4i
Value
Oral GLP-1
Trad. OAD
Insulin
SGLT-2i
1The estimated GLP-1 share of prescriptions is based on volume packs from IQVIA. Volume packs are converted into full-year patients/prescriptions based on WHO assumptions for average daily doses or if not available, Novo Nordisk assumptions.
Note: Other OADs cover: metformin, sulfonylurea, thiazolidinediones. OAD: Oral anti-diabetic
Source: RHS: MIDAS; patient and value figures based on IQVIA MAT, Nov 2023; Market values are based on the list prices
Novo NordiskⓇView entire presentation